The industry has already proven what AI can do. The harder, more interesting work is making it perform inside a live pharmaceutical operation. That is exactly the conversation AutomaPlus 2026 is built around.
Let’s be honest. Pharma does not need another debate about whether AI will change the industry. That debate is over, and AI won.
The question worth asking now is quieter, more practical, and far more consequential: what happens when AI, automation and digital systems leave the comfort of the pilot and walk onto the plant floor?
An AI model might work. A digital twin might work. Predictive maintenance might work. In isolation, almost everything works.
But pharmaceutical manufacturing has never run on isolated technologies. It runs on systems that must speak to one another, data that must be trusted, processes that must stay compliant, and people who must act confidently on what the screen tells them.
That is the harder problem. And it is precisely where the next chapter of pharma digitalisation will be won or lost.
The Gap Between the Pilot and the Plant
Anyone who has taken a promising proof of concept into production knows the feeling. The pilot dazzles. Then reality arrives.
Data lives in scattered systems. Equipment runs on different architectures. GMP requirements cannot be bolted on afterwards; they have to be designed in from the start. And the solution that sings at one site can stumble at the next.
This is the moment digitalisation stops being a technology story and becomes an implementation story.
A predictive maintenance system earns its place only when its insight changes an actual maintenance decision. A digital twin matters only when it is fed by reliable, live operational data. AI creates value only when its output becomes a natural part of someone’s daily workflow.
So the next leap forward may have less to do with adding new technology and more to do with making existing technology work together, intelligently and compliantly, at scale.
The People Behind the Technology
This is what makes the ecosystem around pharma digitalisation so compelling right now, and why AUTOMAPLUS 2026 deserves a place on your calendar.
The programme brings together professionals from Takeda, GSK, Novo Nordisk, Bachem, Kenvue, Johnson & Johnson and Merck Life Science, alongside specialists in automation, engineering and industrial digitalisation.
That mix offers something far more valuable than another glossy technology showcase. It offers a genuine window into what global pharmaceutical organisations are actually trying to solve.
Because the question has shifted. It is no longer simply, “What technology is being adopted?”
It is now, “What problem is the industry trying to solve with it?”
Get that answer right, and your roadmap, your product strategy and your partnerships all come into sharper focus.
Why India Should Be Paying Close Attention
For Indian pharma, the timing could hardly be better.
As the industry moves deeper into complex products, biologics, biosimilars and higher-value manufacturing, the technology expectations surrounding those operations are rising in step. What sufficed for yesterday’s portfolio will not carry tomorrow’s.
For Indian companies with global ambitions, understanding this shift is not optional. It is a competitive advantage.
What are global manufacturers investing in? Where are the stubborn gaps? What will they expect from their technology and engineering partners over the next five years?
These answers rarely live in a market report. They surface in conversations with the people wrestling with these challenges every day. That is true whether you are a manufacturer refining your digital roadmap, or an Indian automation, engineering, software or equipment company looking to earn a seat at the global table.
Inside AutomaPlus 2026
AutomaPlus carries this conversation across the full value chain: R&D, manufacturing, packaging and supply chain. Its industry-led cases cover the themes that define the pilot-to-plant challenge, including AI and smart data, predictive maintenance, digital twins, smart packaging and digital compliance.
Just as importantly, the room itself is designed for real exchange. Pharma companies, contract manufacturers, API producers, equipment providers and service companies come together in one place, making it as much a meeting ground for partnerships as a forum for ideas.
And perhaps that is the real value of looking at pharma digitalisation today. Not chasing whatever technology comes next, but understanding how the industry is genuinely putting technology to work.
AutomaPlus 2026
16-17 November 2026 | Zürich, Switzerland
Two days spanning R&D → Manufacturing → Packaging → Supply Chain, with industry-led cases, candid discussions and focused networking.
If your organisation is building, buying or enabling the next generation of pharmaceutical operations, this is where the practical conversations are happening. Zürich is where you will want to be.
